Completed PHASE2 INTERVENTIONAL 2-arm NCT01467232

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting (IMPACT-CABG)

Implantation of Autologous CD133+ Stem Cells in Patients Undergoing CABG

Sponsor: Miltenyi Biotec, Inc.

Conditions Coronary Artery Bypass Surgery Heart Attack Heart Failure

Interventions Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting

Updated 5 times since 2017 Last updated: Nov 30, 2015 Started: Sep 30, 2011 Primary completion: Nov 30, 2014 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Coronary Artery Bypass Surgery and Heart Attack, this trial is completed. The trial is conducted by Miltenyi Biotec, Inc. and has accumulated 5 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Miltenyi Biotec, Inc.
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada